Court Invalidates Kaneka Patent Claims for Ubiquinol
The ruling enables Cocrystal Technology to continue U.S. distribution of its CoQ10 ingredient, CrysQnol, without restriction.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Should courts limit patent protections to ensure easier market access for alternative health ingredient suppliers?
On September 2, 2026, the U.S. District Court for the Eastern District of New York invalidated two Kaneka Corporation patent claims regarding ubiquinol. This ruling effectively allows Cocrystal Technology to continue the manufacture and sale of its reduced CoQ10 ingredient, known as CrysQnol, within the United States.
Why it matters
The decision clarifies the competitive landscape for reduced CoQ10 suppliers by removing significant intellectual property barriers. It underscores the stringent U.S. requirements for patent utility and enablement in the dietary supplement and ingredient sector.
The court invalidated two patent claims in case 1:23-cv-07483, citing a fundamental lack of utility and enablement. These requirements determine if a patent provides enough information for a person skilled in the field to use the invention effectively.
The players
Kaneka Corporation
A Japanese chemical manufacturing company that develops and holds various patents for ubiquinol and CoQ10 derivatives.
Cocrystal Technology
A Jiaxing, China-based manufacturer of nutritional ingredients that produces the reduced CoQ10 supplement now branded as CrysQnol.
The details
The court ruled that Kaneka failed to meet U.S. patent law requirements for enablement—the technical disclosure allowing others to practice the invention—and utility. This legal threshold demands that a patent clearly demonstrate the practical application of the claimed technology. Consequently, Cocrystal Technology has moved to consolidate its global ingredient portfolio under the unified CrysQnol brand identity.
Timeline
2023: The patent dispute between Kaneka and Cocrystal Technology began.
September 2, 2026: The court issued the order invalidating the patent claims.
October 15, 2026: Cocrystal Technology announced the court ruling.
The Tech Race
The ruling marks a resolution to a three-year legal conflict between these two industry competitors. It establishes a clearer market path for Cocrystal Technology as it seeks to expand its footprint in the U.S. ingredient supply chain.
The ruling ensures the continued availability of CrysQnol for manufacturers and supplement companies operating in the U.S. market. No direct consumer pricing changes were announced, though the legal clearance effectively removes a barrier for Cocrystal Technology's distribution operations.
The takeaway
This decision reinforces the high evidentiary bar for maintaining chemical manufacturing patents in the United States. Observers should track any potential appeals filed by Kaneka Corporation in the coming months, as such actions could restart the litigation timeline.
Further reading
For broader trends in intellectual property litigation within the life sciences, visit Biotech.
Source note: This article includes information reported by Supplysidesj.
Live Poll
Should courts limit patent protections to ensure easier market access for alternative health ingredient suppliers?
